## Ernest Mazzaferri Thyroid Cancer Conference

Saturday, November 3 Hilton Polaris Gemini Ballroom

#### Agenda

### 7:15 a.m. Registration, Breakfast and Visit Vendors

#### 8 a.m. Introduction and Welcome Matthew Ringel, MD

Director, Division of Endocrinology, Diabetes, and Metabolism Co-Director, Thyroid Cancer Unit Co-Leader, Molecular Biology and Cancer Genetics Program The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James)

### Jennifer Sipos, MD

Professor, Division of Endocrinology and Metabolism Director of Benign Thyroid Disorders Program OSUCCC-James

# Session One: Defining Pathways of Thyroid Cancer: Development and Progression Session Chair: Matthew Ringel, MD

- 8:10 a.m. Genetic Changes in Metastatic Thyroid Cancer: Defining New Therapeutic Targets Matthew Ringel, MD OSUCCC-James
- 8:50 a.m. The Somatic Genome of Hürthle Cell Carcinoma of the Thyroid Featured Speaker: David McFadden, MD, PhD Assistant Professor, Internal Medicine University of Texas Southwestern Medical Center



WEXNER MEDICAL CENTER

## **Agenda Continued**

- 9:30 a.m. The Role of Tumor Microenvironment in Thyroid Cancer Lawrence Andrew "Drew" Shirley, MD, MS Assistant Professor, Division of Surgical Oncology OSUCCC – James
- 10:05 a.m. Mid-Morning Break and Visit Vendors
- 10:25 a.m. Recent Developments in Molecular Markers for Thyroid Nodules Jennifer Sipos, MD OSUCCC – James
- 11:05 a.m. Fukushima Disaster Aftermath Mayumi Endo, MD Assistant Professor, Division of Endocrinology, Diabetes and Metabolism OSUCCC-James
- 11:45 a.m. Lunch and Visit Vendors

Clinical Debate/Challenging Case Management Discussions Moderator: Matthew Ringel, MD OSUCCC – James

Panelists: Jennifer Sipos, MD OSUCCC – James

John Phay, MD Associate Professor, Division of Surgical Oncology OSUCCC – James

Amit Agrawal, MD Assistant Professor, Department of Otolaryngology OSUCCC – James



## **Agenda Continued**

## Session Two: Thyroid Cancer Management Session Chair: Jennifer Sipos, MD

1 p.m. Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications Featured Speaker: Douglas Van Nostrand, MD, FACP, FACNM Director, Nuclear Medicine Research MedStar Health Research Institute and Washington Hospital Center Washington, D.C. Representative, Society of Nuclear Medicine

1:40 p.m. Inappropriate Use of Therapy for Low Risk Thyroid Cancer Featured Speaker: Megan Haymart, MD Associate Professor, Medicine

University of Michigan

- 2:20 p.m. Salivary Damage from Radioactive Iodine Sissy Jhiang, PhD Professor, Physiology and Cell Biology OSUCCC-James
  - **3 p.m.** Lobectomy vs. Total Thyroidectomy

#### Matthew Old, MD

Associate Professor and Director, Division of Head & Neck Oncologic Surgery Program Director, Head and Neck Service Line OSUCCC-James



## **Agenda Continued**

- 3:40 p.m. Systemic Therapies for the Management of Radioactive Iodine Refractory Differentiated Thyroid Cancer Bhavana Konda, MD, MPH Assistant Professor, Division of Medical Oncology OSUCCC – James
- 4:15 p.m. Concluding Remarks and Evaluation
- 4:30 p.m. Adjourn

